Pickar-Oliver, Adrian
Black, Joshua B.
Lewis, Mae M.
Mutchnick, Kevin J.
Klann, Tyler S.
Gilcrest, Kylie A. http://orcid.org/0000-0002-4053-1979
Sitton, Madeleine J.
Nelson, Christopher E.
Barrera, Alejandro
Bartelt, Luke C.
Reddy, Timothy E. http://orcid.org/0000-0002-7629-061X
Beisel, Chase L. http://orcid.org/0000-0003-0650-9943
Barrangou, Rodolphe
Gersbach, Charles A. http://orcid.org/0000-0003-1478-4013
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (F31NS105419, 1R35GM119561-01, DP2OD008586, T32GM008555)
Article History
Received: 25 April 2019
Accepted: 23 July 2019
First Online: 23 September 2019
Competing interests
: C.A.G., A.P.-O., R.B. and C.L.B. have filed patent applications related to genome engineering with type I CRISPR systems. T.S.K. is a co-founder of, and advisor to, Element Genomics. C.A.G. is a co-founder of, and advisor to, Locus Biosciences and Element Genomics, and an advisor to Sarepta Therapeutics. R.B. is a co-founder and Scientific Advisory Board member of Locus Biosciences and Intellia Therapeutics. C.L.B. is a co-founder and Scientific Advisory Board member of Locus Biosciences.